Further, this same study suggested that the frequency of biomarker monitoring for cardiotoxicity during and after anthracycline therapy should depend upon baseline risk factors for cardiovascular disease, with the highest risk patients obtaining NT-proBNP and troponin levels prior to the second, fourth, and sixth cycles of chemotherapy [25]. This evidence concerns the gene NPPB and cardiovascular disorder.